Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891157069> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2891157069 endingPage "TPS7073" @default.
- W2891157069 startingPage "TPS7073" @default.
- W2891157069 abstract "TPS7073 Background: Glasdegib is an oral Hedgehog pathway inhibitor with clinical activity in patients (pts) with untreated AML or higher-risk MDS, and improved survival when combined with low-dose cytarabine (AraC) in unfit pts with AML. BRIGHT AML1019 comprises two Phase 3, randomized (1:1), double-blind trials evaluating glasdegib 100 mg once daily (QD) or placebo (PBO) + chemotherapy in untreated adult AML (NCT03416179). The protocol includes 2 parallel, simultaneous trials: 1 with intensive chemotherapy (IC) and 1 with nonintensive chemotherapy (nIC). Methods: Both trials include pts aged ≥18 y with untreated AML (WHO 2016), including AML evolved from MDS or antecedent hematologic disease, or secondary AML. Key exclusions: inadequate organ function, acute promyelocytic leukemia, active CNS leukemia. Assignment to IC or nIC trial is per Investigator. In the IC trial, 400 pts are randomized (1:1) to glasdegib 100 mg QD or PBO on Day 1 and continue for up to 2 y or until post consolidation minimal residual disease (MRD)-negative status. Glasdegib or PBO are administered with 7+3 induction (AraC 100 mg/m2 IV for 7 days + daunorubicin 60 mg/m2 for 3 days); induction 2, if needed, will use 7+3 or 5+2. Consolidation consists of single-agent AraC 1 or 3 g/m2 IV over 3 h twice daily on Days 1, 3 and 5 every 28 days for ≤4 cycles; eligible patients may receive hematopoietic stem cell transplant. In the nIC trial, 320 pts are randomized (1:1) to glasdegib 100 mg QD or PBO, each with azacitidine 75 mg/m2 daily SC or IV for 7 days, in 28-day cycles. Treatments continue until disease progression, unacceptable toxicity, withdrawal or death. In both trials, glasdegib and PBO continue regardless of chemotherapy dose modifications/delays. The primary endpoint is overall survival. Secondary endpoints include response, time to and duration of response, event-free survival, safety, patient-reported outcomes and pharmacokinetics. Clinical trial information: NCT03416179." @default.
- W2891157069 created "2018-09-27" @default.
- W2891157069 creator A5000436961 @default.
- W2891157069 creator A5015101485 @default.
- W2891157069 creator A5017474182 @default.
- W2891157069 creator A5023058199 @default.
- W2891157069 creator A5029834788 @default.
- W2891157069 creator A5045768565 @default.
- W2891157069 creator A5051224380 @default.
- W2891157069 creator A5055740968 @default.
- W2891157069 creator A5058767582 @default.
- W2891157069 creator A5064813521 @default.
- W2891157069 creator A5071270259 @default.
- W2891157069 creator A5083522292 @default.
- W2891157069 date "2018-05-20" @default.
- W2891157069 modified "2023-10-15" @default.
- W2891157069 title "Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia." @default.
- W2891157069 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.tps7073" @default.
- W2891157069 hasPublicationYear "2018" @default.
- W2891157069 type Work @default.
- W2891157069 sameAs 2891157069 @default.
- W2891157069 citedByCount "4" @default.
- W2891157069 countsByYear W28911570692019 @default.
- W2891157069 countsByYear W28911570692021 @default.
- W2891157069 crossrefType "journal-article" @default.
- W2891157069 hasAuthorship W2891157069A5000436961 @default.
- W2891157069 hasAuthorship W2891157069A5015101485 @default.
- W2891157069 hasAuthorship W2891157069A5017474182 @default.
- W2891157069 hasAuthorship W2891157069A5023058199 @default.
- W2891157069 hasAuthorship W2891157069A5029834788 @default.
- W2891157069 hasAuthorship W2891157069A5045768565 @default.
- W2891157069 hasAuthorship W2891157069A5051224380 @default.
- W2891157069 hasAuthorship W2891157069A5055740968 @default.
- W2891157069 hasAuthorship W2891157069A5058767582 @default.
- W2891157069 hasAuthorship W2891157069A5064813521 @default.
- W2891157069 hasAuthorship W2891157069A5071270259 @default.
- W2891157069 hasAuthorship W2891157069A5083522292 @default.
- W2891157069 hasConcept C126322002 @default.
- W2891157069 hasConcept C142724271 @default.
- W2891157069 hasConcept C143998085 @default.
- W2891157069 hasConcept C168563851 @default.
- W2891157069 hasConcept C204787440 @default.
- W2891157069 hasConcept C27081682 @default.
- W2891157069 hasConcept C2776611710 @default.
- W2891157069 hasConcept C2776694085 @default.
- W2891157069 hasConcept C2778041864 @default.
- W2891157069 hasConcept C2778729363 @default.
- W2891157069 hasConcept C535046627 @default.
- W2891157069 hasConcept C71924100 @default.
- W2891157069 hasConcept C90924648 @default.
- W2891157069 hasConceptScore W2891157069C126322002 @default.
- W2891157069 hasConceptScore W2891157069C142724271 @default.
- W2891157069 hasConceptScore W2891157069C143998085 @default.
- W2891157069 hasConceptScore W2891157069C168563851 @default.
- W2891157069 hasConceptScore W2891157069C204787440 @default.
- W2891157069 hasConceptScore W2891157069C27081682 @default.
- W2891157069 hasConceptScore W2891157069C2776611710 @default.
- W2891157069 hasConceptScore W2891157069C2776694085 @default.
- W2891157069 hasConceptScore W2891157069C2778041864 @default.
- W2891157069 hasConceptScore W2891157069C2778729363 @default.
- W2891157069 hasConceptScore W2891157069C535046627 @default.
- W2891157069 hasConceptScore W2891157069C71924100 @default.
- W2891157069 hasConceptScore W2891157069C90924648 @default.
- W2891157069 hasIssue "15_suppl" @default.
- W2891157069 hasLocation W28911570691 @default.
- W2891157069 hasOpenAccess W2891157069 @default.
- W2891157069 hasPrimaryLocation W28911570691 @default.
- W2891157069 hasRelatedWork W2016381406 @default.
- W2891157069 hasRelatedWork W2020667184 @default.
- W2891157069 hasRelatedWork W2034612532 @default.
- W2891157069 hasRelatedWork W2383814905 @default.
- W2891157069 hasRelatedWork W2405192714 @default.
- W2891157069 hasRelatedWork W2418464324 @default.
- W2891157069 hasRelatedWork W2900543606 @default.
- W2891157069 hasRelatedWork W3010336760 @default.
- W2891157069 hasRelatedWork W3032889600 @default.
- W2891157069 hasRelatedWork W3133176200 @default.
- W2891157069 hasVolume "36" @default.
- W2891157069 isParatext "false" @default.
- W2891157069 isRetracted "false" @default.
- W2891157069 magId "2891157069" @default.
- W2891157069 workType "article" @default.